These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 12412209)

  • 1. Etanercept in systemic juvenile idiopathic arthritis.
    Russo RA; Katsicas MM; Zelazko M
    Clin Exp Rheumatol; 2002; 20(5):723-6. PubMed ID: 12412209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.
    Katsicas MM; Russo RA
    Clin Exp Rheumatol; 2005; 23(4):545-8. PubMed ID: 16095128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
    Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study.
    Schmeling H; Mathony K; John V; Keysser G; Burdach S; Horneff G
    Ann Rheum Dis; 2001 Apr; 60(4):410-2. PubMed ID: 11247875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.
    Giannini EH; Ilowite NT; Lovell DJ; Wallace CA; Rabinovich CE; Reiff A; Higgins G; Gottlieb B; Singer NG; Chon Y; Lin SL; Baumgartner SW;
    Arthritis Rheum; 2009 Sep; 60(9):2794-804. PubMed ID: 19714630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.
    Papsdorf V; Horneff G
    Rheumatology (Oxford); 2011 Jan; 50(1):214-21. PubMed ID: 21148155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.
    Lan JL; Chou SJ; Chen DY; Chen YH; Hsieh TY; Young M
    J Formos Med Assoc; 2004 Aug; 103(8):618-23. PubMed ID: 15340661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.
    Wallace CA; Giannini EH; Spalding SJ; Hashkes PJ; O'Neil KM; Zeft AS; Szer IS; Ringold S; Brunner HI; Schanberg LE; Sundel RP; Milojevic DS; Punaro MG; Chira P; Gottlieb BS; Higgins GC; Ilowite NT; Kimura Y; Johnson A; Huang B; Lovell DJ;
    J Rheumatol; 2014 Jun; 41(6):1163-70. PubMed ID: 24786928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept.
    Borte S; Liebert UG; Borte M; Sack U
    Rheumatology (Oxford); 2009 Feb; 48(2):144-8. PubMed ID: 19074187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
    Funk RS; Chan MA; Becker ML
    Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis.
    Haapasaari J; Kautiainen H; Hannula S; Pohjankoski H; Hakala M
    Clin Exp Rheumatol; 2002; 20(6):867-70. PubMed ID: 12508784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
    Nerome Y; Imanaka H; Nonaka Y; Takei S
    Mod Rheumatol; 2007; 17(6):526-8. PubMed ID: 18084710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Kurosawa R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2011 Dec; 21(6):572-8. PubMed ID: 21479889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A.
    Gül U; Gönül M; Kiliç A; Erdem R; Cakmak SK; Gündüz H
    Clin Ther; 2006 Feb; 28(2):251-4. PubMed ID: 16678646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
    Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Davies R; Southwood TR; Kearsley-Fleet L; Lunt M; Hyrich KL;
    Arthritis Rheumatol; 2015 Sep; 67(9):2487-94. PubMed ID: 25989609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.
    Su Y; Yang YH; Chiang BL
    Clin Rheumatol; 2017 Sep; 36(9):1997-2004. PubMed ID: 28540607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.